Urovant Sciences Ltd. UROV
We take great care to ensure that the data presented and summarized in this overview for Urovant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in UROV
Top Purchases
Top Sells
About UROV
Insider Transactions at UROV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2021
|
Myrtle S Potter Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,480
-100.0%
|
-
|
|
Mar 29
2021
|
Christine Ocampo PAO; CAO/Urovant Sciences,Inc. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
78,781
-100.0%
|
-
|
|
Mar 29
2021
|
Bryan E. Smith GC/Urovant Sciences, Inc. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
124,447
-100.0%
|
-
|
|
Mar 29
2021
|
Walt Johnston Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
109,139
-100.0%
|
-
|
|
Mar 29
2021
|
Sef Kurstjens Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,480
-100.0%
|
-
|
|
Mar 29
2021
|
James M. Hindman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-100.0%
|
-
|
|
Mar 29
2021
|
Ajay Bansal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
140,098
-100.0%
|
-
|
|
Mar 29
2021
|
Pierre Legault Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,480
-100.0%
|
-
|
|
Mar 29
2021
|
Cornelia Haag Molkenteller CMO/Urovant Sciences, Inc. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
141,348
-100.0%
|
-
|
|
Mar 29
2021
|
James A. Robinson Jr. PEO;CEO/Urovant Sciences, Inc. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,385
-100.0%
|
-
|
|
Jan 10
2021
|
James A. Robinson Jr. PEO;CEO/Urovant Sciences, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,095
-32.81%
|
$65,520
$16.11 P/Share
|
|
Jan 07
2021
|
Bryan E. Smith GC/Urovant Sciences, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,761
-3.68%
|
$76,176
$16.09 P/Share
|
|
Jan 07
2021
|
Cornelia Haag Molkenteller CMO/Urovant Sciences, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
5,810
-3.95%
|
$92,960
$16.09 P/Share
|
|
Jun 19
2019
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,957
+0.02%
|
$39,656
$8.17 P/Share
|
|
Jun 18
2019
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
6,706
+0.03%
|
$53,648
$8.21 P/Share
|
|
Jun 17
2019
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
6,541
+0.03%
|
$52,328
$8.53 P/Share
|
|
Jun 14
2019
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,144
+0.03%
|
$50,008
$7.91 P/Share
|
|
Jun 13
2019
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,367
+0.03%
|
$51,569
$7.95 P/Share
|
|
Jun 12
2019
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,500
+0.03%
|
$60,000
$8.3 P/Share
|
|
Jun 11
2019
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,189
+0.03%
|
$57,512
$8.58 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders